These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10694554)

  • 1. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
    Nam RK; Diamandis EP; Toi A; Trachtenberg J; Magklara A; Scorilas A; Papnastasiou PA; Jewett MA; Narod SA
    J Clin Oncol; 2000 Mar; 18(5):1036-42. PubMed ID: 10694554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
    Magklara A; Scorilas A; Catalona WJ; Diamandis EP
    Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection.
    Nam RK; Zhang WW; Trachtenberg J; Diamandis E; Toi A; Emami M; Ho M; Sweet J; Evans A; Jewett MA; Narod SA
    J Clin Oncol; 2003 Jun; 21(12):2312-9. PubMed ID: 12805332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
    Bachour DM; Chahin E; Al-Fahoum S
    Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
    Becker C; Noldus J; Diamandis E; Lilja H
    Crit Rev Clin Lab Sci; 2001 Oct; 38(5):357-99. PubMed ID: 11720279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
    Haese A; Becker C; Noldus J; Graefen M; Huland E; Huland H; Lilja H
    J Urol; 2000 May; 163(5):1491-7. PubMed ID: 10751864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
    Haese A; Graefen M; Becker C; Noldus J; Katz J; Cagiannos I; Kattan M; Scardino PT; Huland E; Huland H; Lilja H
    Prostate; 2003 Feb; 54(3):181-6. PubMed ID: 12518322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.